Kezar Life Sciences (NASDAQ:KZR) Receives “Neutral” Rating from HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports.

Kezar Life Sciences Stock Down 0.7 %

Shares of Kezar Life Sciences stock opened at $0.85 on Monday. Kezar Life Sciences has a 12-month low of $0.52 and a 12-month high of $1.14. The firm has a market capitalization of $61.71 million, a PE ratio of -0.61 and a beta of 0.21. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. The stock’s fifty day moving average is $0.63 and its 200-day moving average is $0.69.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Equities analysts anticipate that Kezar Life Sciences will post -1.2 earnings per share for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC acquired a new position in shares of Kezar Life Sciences in the 2nd quarter valued at about $630,000. BNP Paribas Financial Markets lifted its position in Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after buying an additional 71,543 shares in the last quarter. Vanguard Group Inc. lifted its position in Kezar Life Sciences by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after buying an additional 30,740 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Kezar Life Sciences by 42.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after buying an additional 534,203 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Kezar Life Sciences during the 2nd quarter valued at $63,000. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.